Daily Sepsis Research Analysis
Three papers stood out today: a mechanistically innovative study linking rare deleterious LTBP4 variants to the most severe pediatric sepsis phenotype; a hospital transmission analysis integrating CFD with epidemiology that quantifies how distance and room configuration shape SARS-CoV-2 spread; and a single-arm phase 1b/2 trial showing promising activity and manageable safety of enasidenib plus venetoclax in relapsed/refractory IDH2-mutated AML.
Summary
Three papers stood out today: a mechanistically innovative study linking rare deleterious LTBP4 variants to the most severe pediatric sepsis phenotype; a hospital transmission analysis integrating CFD with epidemiology that quantifies how distance and room configuration shape SARS-CoV-2 spread; and a single-arm phase 1b/2 trial showing promising activity and manageable safety of enasidenib plus venetoclax in relapsed/refractory IDH2-mutated AML.
Research Themes
- Genetic architecture and endotypes of severe pediatric sepsis
- Nosocomial respiratory virus transmission and spatial modeling
- Targeted combination therapy in relapsed/refractory IDH2-mutated AML
Selected Articles
1. The role of spatial distance in SARS-CoV-2 nosocomial transmission.
By integrating CFD with epidemiologic reconstruction, the study quantifies a ~40% drop in exposure per metre of distance and a four-fold reduction with single rooms, yet only 72% of ward transmissions were explained by these spatial factors. Distance-independent mechanisms likely drive a substantial fraction of nosocomial spread, indicating single-room strategies alone are insufficient.
Impact: Combining CFD with real-world epidemiology provides actionable, quantitative insights that challenge reliance on spatial distancing alone for infection control.
Clinical Implications: Hospitals should pair single-room strategies with comprehensive infection prevention, including staff workflow controls, shared-facility hygiene, ventilation/airflow management, and surveillance to address non-distance transmission routes.
Key Findings
- Exposure decreased by ~40% for each additional metre of distance from the infected host.
- Single-room placement yielded an additional four-fold reduction in exposure risk.
- Only 72% (95% CI 45%-96%) of transmissions were explained by spatial factors, implicating distance-independent routes such as shared facilities or staff-mediated transmission.
Methodological Strengths
- Integration of CFD simulations with epidemiological reconstruction for mechanistic quantification
- Statistical inference to estimate the proportion of transmissions attributable to spatial factors
Limitations
- Potential generalizability limits (elderly medicine wards) and unmeasured confounders
- Model assumptions in CFD and incomplete accounting for all transmission pathways
Future Directions: Quantify contributions of staff-mediated and shared-space transmissions, test interventions (ventilation upgrades, workflow redesign), and validate models across diverse ward types and pathogens.
BACKGROUND: The nosocomial transmission of respiratory viruses causes significant disruption to hospital care, but the spatial dynamics of transmission on hospital wards are poorly understood. METHODS: We developed a model integrating computational fluid dynamics (CFD) simulations into an epidemiological reconstruction of virus transmission to quantify the relationship between SARS-CoV-2 transmission and the location of beds in medicine for the elderly wards. FINDINGS: Data from CFD simulations described a pattern in which exposure to an infected host decreased by approximately 40% for each additional metre of distance, with a further four-fold reduction when patients were in separate rooms. However, statistical inference suggested that only 72% (95% confidence interval 45%-96%) of the transmission events identified on wards could be explained by this model. Other cases of transmission occurred at distances too great to be consistent with the simulation model, suggesting that distance-independent mechanisms such as shared facilities or staff-mediated transmission had an important role in nosocomial transmission. CONCLUSION: Our results suggest that while spatial separation reduces transmission risk, infection prevention and control strategies such as the use of single-bed rooms may be insufficient to prevent outbreaks. Comprehensive approaches to preventing nosocomial transmission, addressing multiple potential viral transmission pathways, are necessary.
2. Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial.
In 27 patients with IDH2-mutated R/R AML or MDS, enasidenib plus venetoclax yielded a 62% overall response (50% complete remission in AML) with no dose-limiting toxicities or treatment-related deaths; infections (including sepsis 19%) were common. Recommended phase 2 doses were venetoclax 400 mg daily and enasidenib 100 mg daily.
Impact: Demonstrates clinically meaningful activity and manageable safety of a biologically synergistic combination in a hard-to-treat molecularly defined population.
Clinical Implications: Supports further randomized evaluation of enasidenib plus venetoclax in IDH2-mutated R/R AML and careful infection risk mitigation (including sepsis) during therapy.
Key Findings
- Overall response rate 62% in AML (13/26 complete remissions, 50%).
- No dose-limiting toxicities or treatment-related deaths; recommended doses: venetoclax 400 mg daily, enasidenib 100 mg daily.
- Common grade ≥3 events included febrile neutropenia (41%), infections (30%), pneumonia (22%), and sepsis (19%).
Methodological Strengths
- Prospective multicentre design with trial registration (NCT04092179)
- Clear safety and efficacy endpoints with intention-to-treat response assessment
Limitations
- Single-arm design without comparator limits causal inference
- Small sample size and limited generalizability; only one MDS patient
Future Directions: Proceed to randomized controlled trials testing this combination versus standard regimens, with correlative biomarkers and infection-mitigation strategies.
BACKGROUND: Enasidenib, a mutant IDH2 inhibitor, is used to treat IDH2-mutated acute myeloid leukaemia (AML). Preclinical studies have demonstrated synergy between enasidenib and venetoclax, a BCL2 inhibitor, in IDH2-mutated AML. The aim of this study was to evaluate the safety and activity of enasidenib plus venetoclax in patients with relapsed or refractory IDH2-mutated AML or myelodysplastic syndromes (MDS). METHODS: The ENAVEN-AML study was a single-arm, phase 1b/2 trial conducted at two centres in Canada. Patients were eligible to participate if they were 18 years or older, had an Eastern Cooperative Oncology Group performance status of 0 to 2, had a confirmed IDH2 mutation (affecting Arg140 or Arg172), and had AML or MDS that was refractory or had relapsed after at least one line of treatment. Patients were treated with venetoclax 400 mg orally daily with a 3-day dose ramp-up starting on cycle 1 day 1 and enasidenib 100 mg orally daily starting on cycle 1 day 15. The primary endpoint of the phase 1b portion was safety, which included dose-limiting toxicity and the frequency and severity of treatment-emergent adverse events (TEAEs), as well as determining the maximum tolerated dose and recommended phase 2 dose. The primary objective of the phase 2 portion was to assess preliminary activity, with overall response rate by intention-to-treat as the primary endpoint. Assessment of safety and activity were determined on the pooled analysis data from the phase 1 and 2 studies. The ENAVEN-AML study is registered with ClinicalTrials.gov (NCT04092179) and is completed. FINDINGS: From Nov 12, 2020, to July 5, 2022, the study enrolled 27 patients (13 in phase 1b, 14 in phase 2) and the median follow-up was 20·2 months (IQR 15·0-23·0) at the data cutoff on Sept 30, 2023. The median age was 70 years (IQR 55-76); 16 (59%) of 27 patients were male, 11 (41%) female, and 19 (70%) White. 26 patients had relapsed or refractory AML, and one patient had relapsed MDS. The most common grade 3 or worse TEAEs were febrile neutropenia (n=11, 41%), infections (n=8, 30%), thrombocytopenia (n=7, 26%), pneumonia (n=6, 22%), sepsis (n=5, 19%), and anaemia (n=5, 19%). One case of IDH inhibitor-associated differentiation syndrome was observed. Serious adverse events were reported in 17 (62%) of 27 patients, most commonly infections (n=11, 41%) and intracranial bleeding (n=5, 19%). No dose-limiting toxicities or treatment-related deaths were observed. The recommended phase 2 dose was 400 mg daily for venetoclax and 100 mg daily for enasidenib. Of the 26 patients with AML, the overall response rate was 62% (95% CI 41-80; 16 of 26), with 13 (50%) of 26 having complete remission. The only patient with MDS did not respond to enasidenib plus venetoclax. INTERPRETATION: Enasidenib plus venetoclax is safe, with no unexpected TEAEs or treatment-related deaths, and shows preliminary activity in patients with relapsed or refractory IDH2-mutated AML and MDS. FUNDING: AbbVie and Bristol Myers Squibb.
3. Deleterious variants in LTBP4 are associated with severe pediatric sepsis.
Whole-exome, gene-based aggregation identified LTBP4 as exome-wide significant for the hyperinflammatory, worst-outcome PedSep-D phenotype, with PLA2G4E and CCDC157 suggestively associated. Variants showed predicted deleteriousness and gene-specific cytokine patterns, implicating inflammation and immune activation pathways.
Impact: Links a computable sepsis endotype to rare deleterious variants, advancing molecular stratification beyond clinical and cytokine profiles.
Clinical Implications: Supports development of genotype-informed risk stratification and biomarker panels for severe pediatric sepsis, and motivates pathway-focused therapeutics targeting inflammation/immune activation.
Key Findings
- LTBP4 reached exome-wide significance for association with the PedSep-D hyperinflammatory phenotype.
- PLA2G4E and CCDC157 showed suggestive associations with PedSep-D.
- LTBP4 variants were enriched for predicted deleterious effects, and carriers showed gene-specific cytokine changes.
Methodological Strengths
- Gene-based rare variant aggregation within a multicentre pediatric sepsis cohort
- Use of functional prediction metrics and cytokine profiling for biological plausibility
Limitations
- Sample size and replication cohort not specified; risk of false positives
- Lack of functional validation to confirm causal mechanisms
Future Directions: Validate associations in independent cohorts, perform functional assays to probe LTBP4-mediated pathways (e.g., TGF-β signaling), and test genotype-informed stratified interventions.
BACKGROUND: Sepsis is a leading global health burden in children, and its unavoidable heterogeneity has hindered providing therapies beyond antibiotics and supportive care. Recently, we identified four computable phenotypes showing distinct cytokine profiles, clinical outcomes, and therapeutic response characteristics (PedSep-A, B, C, and D) in a multicenter pediatric sepsis cohort. METHODS: In the cohort data, we collected whole-exome sequencing data and identified rare variants associated with PedSep-D phenotype by conducting a gene-based analysis in an aggregated fashion. RESULTS: As a result, one whole-exome significant gene (LTBP4) and two suggestive significant genes (PLA2G4E, CCDC157) showed association with PedSep-D, the phenotype characterized by the most severe outcomes and highest inflammation. The associated variants in LTBP4 were enriched for predicted deleterious effects based on established functional prediction metrics. All three associated genes are implicated in inflammation and immune cell activation based on existing gene function and expression data. Although the circulating cytokine profiles were overlapping between the rare variant carriers, we also identified gene-specific cytokine changes. CONCLUSION: Altogether, our study provides valuable insights into the genetic architecture of a pediatric sepsis phenotype with the highest inflammation level and the most severe outcomes, highlighting potential candidate genes and pathways for further biomarker and therapeutic studies. IMPACT: Pediatric sepsis exhibits substantial heterogeneity, with genetic variation contributing to this variability. Rare variants in LTBP4 are significantly associated with the most severe pediatric sepsis phenotype (PedSep-D), while variants in PLA2G4E and CCDC157 show associations with this phenotype in suggestive significance. Expands on the concept of sepsis phenotypes (PedSep-A, B, C, D) by incorporating genetic insights, moving beyond clinical and cytokine profiles to uncover molecular drivers. Opens new avenues for mechanistic studies to understand the genetic underpinnings of severe inflammation and immune activation in sepsis.